Legend Biotech Business Model Canvas
Biotech Business Model Canvas: Investor-ready roadmap for value creation and scalable growth
Unlock the full strategic blueprint behind Legend Biotech’s Business Model Canvas — a concise, actionable map of its value propositions, key partners, and revenue drivers. This professional, editable file is perfect for investors, strategists, and founders who need clear, company-specific insights. Purchase the full canvas to benchmark, plan, and scale with confidence.
Partnerships
Global pharma co-development
Strategic alliances with large pharma expand clinical, regulatory, and commercial reach, as Legend’s 2017 collaboration with Janssen (USD 350 million upfront, up to ~USD 2 billion in milestones) provided global regulatory and commercialization scale. Co-development accelerates trials and label expansions while sharing risk and costs. Joint commercialization strengthens market access and post-launch evidence, and structured governance ensures aligned portfolio prioritization.
Academic and clinical centers
Partnerships with leading cancer institutes enabled Legend Biotech’s clinical enrollment and translational research for cilta-cel, approved by the FDA in 2022, and continue to support ongoing registrational and post-marketing studies as of 2024. Access to KOLs refines protocols and endpoints, improving trial efficiency and regulatory dialogue. Real-world evidence generation strengthens payer health-economic cases, while shared biobanking accelerates biomarker discovery.
CDMOs and apheresis networks
CDMOs and apheresis networks extend Legend Biotech’s manufacturing footprint and patient reach, enabling production and collections across multiple geographies; as of 2024 Carvykti (cilta-cel) remains commercially distributed under this model. Standardized apheresis protocols improve starting material quality and reduce turnaround time for vein-to-vein workflows. Surge flexibility with contract partners mitigates demand spikes during launch or label expansions. Quality agreements enforce GMP and chain-of-identity controls across the supply chain.
Regulatory and HTA engagement
Early scientific advice aligns Legend Biotech development with regulatory expectations; CARVYKTI received FDA approval in February 2022, anchoring ongoing dialogue. HTA bodies define evidence requirements for reimbursement and real-world evidence; payer-led managed entry agreements can de-risk adoption. Continuous regulator and HTA engagement speeds submissions and post-approval variations.
- Regulatory: FDA approval Feb 2022
- HTA: informs evidence for reimbursement
- Managed entry: de-risks payer uptake
- Continuous dialogue: accelerates filings/variations
Technology and logistics providers
- Tracking: digital vein-to-vein platforms, 3–6 week TAT
- Cold chain: vapor-phase LN2 < −130C
- Analytics: real-time SPC, predictive maintenance
- Security: HIPAA and 21 CFR Part 11 compliance
USD 350M pharma deal and CDMO/cold-chain partners underpin commercial CAR-T scale (FDA Feb 2022)
Strategic pharma alliances (Janssen deal: USD 350M upfront, up to ~USD 2B), academic/clinical site networks, CDMO/apheresis partners, regulator/HTA engagement and digital cold-chain/analytics partners underpin commercial CARVYKTI scale (FDA approval Feb 2022) and ongoing 2024 registrational/post-marketing activity.
| Metric | Value (2024) |
|---|---|
| FDA approval | Feb 2022 |
| Janssen deal | USD 350M upfront; ~USD 2B milestones |
| Vein-to-vein TAT | 3–6 weeks |
| Cold chain | Vapor-phase LN2 < −130C |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Legend Biotech detailing customer segments, channels, and value propositions across the 9 BMC blocks, reflecting its CAR‑T oncology platform, strategic partnerships, commercialization and R&D model, competitive advantages, risks and investor-ready insights for presentations and funding discussions.
Customizable Excel Spreadsheet
High-level view of Legend Biotech’s business model with editable cells, enabling rapid alignment of R&D, commercialization and partnership strategies while saving hours on formatting.
Activities
Cell therapy R&D
Design and optimization of CAR constructs and cell engineering methods drive Legend Biotech R&D, supporting ciltacabtagene autoleucel (Carvykti) commercialization after FDA approval in 2022. Rigorous preclinical efficacy and safety testing de-risks clinical entry and informs trial design. Platform innovations prioritize durability and safety while IP generation secures competitive positioning.
Clinical development
Execute multi-phase trials across hematologic and select solid tumors via the CARTITUDE program (CARTITUDE-1/2/3/4), leveraging cilta-cel data showing a 97.9% overall response rate in CARTITUDE-1 and FDA approval on February 28, 2022. Expand labels through line extensions and earlier-line studies to broaden indications. Orchestrate global sites, centralized monitoring, and strict data-integrity systems. Patient-centric designs (decentralized visits, home nursing) improve enrollment and outcomes.
GMP manufacturing
Scale GMP autologous processing with stringent QC/QA to support commercial supply of cilta-cel (Carvykti), which has a U.S. list price of about 465,000 per treated patient, driving the need to improve yields and reduce per-patient cost. Optimize cycle time and release testing to shorten vein-to-vein timelines while implementing digital batch records and analytics for real-time deviation control. Validate additional sites and contract partners to add redundancy and capacity for global rollout.
Regulatory and market access
Prepare regulatory submissions, respond to agency queries and meet post-approval commitments for cell therapy products (CARVYKTI received FDA approval in February 2022); build HTA value dossiers and economic models to support cost-effectiveness and budget impact; negotiate list prices, outcomes-based agreements and reimbursement pathways with payers; maintain global compliance and active pharmacovigilance for safety reporting.
- Regulatory filings: FDA approval Feb 2022
- HTA focus: value dossiers & economic models
- Commercial: pricing, outcomes-based contracts
- Compliance: global pharmacovigilance & post-market commitments
Commercialization and medical affairs
Commercialization and medical affairs educate HCPs and referral centers on patient selection and management, coordinate patient services and case management, generate real-world evidence to support uptake and reimbursement, and provide center training, logistics and quality programs; activity intensified following FDA approval in 2022 and global rollout with commercial partners through 2024.
- Educate HCPs/centers on referral and management
- Coordinate patient services & case management
- Generate & disseminate real-world evidence
- Support training, logistics & quality programs
Scale CAR-T autologous manufacturing, preserve CARTITUDE-1 safety/efficacy (ORR 97.9%)
Design and optimize CAR constructs and GMP autologous manufacturing to commercialize cilta-cel (FDA approved Feb 28, 2022), maintain safety/efficacy via preclinical and CARTITUDE trials (CARTITUDE-1 ORR 97.9%), and execute global regulatory, payer negotiations and post-market pharmacovigilance.
| Metric | Value |
|---|---|
| FDA approval | Feb 28, 2022 |
| CARTITUDE-1 ORR | 97.9% |
| US list price | ~465,000 per patient |
Delivered as Displayed
Business Model Canvas
The Business Model Canvas you’re previewing for Legend Biotech is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, fully formatted, and ready to edit. No surprises: what you see is what you’ll download and use.
Biotech Business Model Canvas: Investor-ready roadmap for value creation and scalable growth
Unlock the full strategic blueprint behind Legend Biotech’s Business Model Canvas — a concise, actionable map of its value propositions, key partners, and revenue drivers. This professional, editable file is perfect for investors, strategists, and founders who need clear, company-specific insights. Purchase the full canvas to benchmark, plan, and scale with confidence.
Partnerships
Global pharma co-development
Strategic alliances with large pharma expand clinical, regulatory, and commercial reach, as Legend’s 2017 collaboration with Janssen (USD 350 million upfront, up to ~USD 2 billion in milestones) provided global regulatory and commercialization scale. Co-development accelerates trials and label expansions while sharing risk and costs. Joint commercialization strengthens market access and post-launch evidence, and structured governance ensures aligned portfolio prioritization.
Academic and clinical centers
Partnerships with leading cancer institutes enabled Legend Biotech’s clinical enrollment and translational research for cilta-cel, approved by the FDA in 2022, and continue to support ongoing registrational and post-marketing studies as of 2024. Access to KOLs refines protocols and endpoints, improving trial efficiency and regulatory dialogue. Real-world evidence generation strengthens payer health-economic cases, while shared biobanking accelerates biomarker discovery.
CDMOs and apheresis networks
CDMOs and apheresis networks extend Legend Biotech’s manufacturing footprint and patient reach, enabling production and collections across multiple geographies; as of 2024 Carvykti (cilta-cel) remains commercially distributed under this model. Standardized apheresis protocols improve starting material quality and reduce turnaround time for vein-to-vein workflows. Surge flexibility with contract partners mitigates demand spikes during launch or label expansions. Quality agreements enforce GMP and chain-of-identity controls across the supply chain.
Regulatory and HTA engagement
Early scientific advice aligns Legend Biotech development with regulatory expectations; CARVYKTI received FDA approval in February 2022, anchoring ongoing dialogue. HTA bodies define evidence requirements for reimbursement and real-world evidence; payer-led managed entry agreements can de-risk adoption. Continuous regulator and HTA engagement speeds submissions and post-approval variations.
- Regulatory: FDA approval Feb 2022
- HTA: informs evidence for reimbursement
- Managed entry: de-risks payer uptake
- Continuous dialogue: accelerates filings/variations
Technology and logistics providers
- Tracking: digital vein-to-vein platforms, 3–6 week TAT
- Cold chain: vapor-phase LN2 < −130C
- Analytics: real-time SPC, predictive maintenance
- Security: HIPAA and 21 CFR Part 11 compliance
USD 350M pharma deal and CDMO/cold-chain partners underpin commercial CAR-T scale (FDA Feb 2022)
Strategic pharma alliances (Janssen deal: USD 350M upfront, up to ~USD 2B), academic/clinical site networks, CDMO/apheresis partners, regulator/HTA engagement and digital cold-chain/analytics partners underpin commercial CARVYKTI scale (FDA approval Feb 2022) and ongoing 2024 registrational/post-marketing activity.
| Metric | Value (2024) |
|---|---|
| FDA approval | Feb 2022 |
| Janssen deal | USD 350M upfront; ~USD 2B milestones |
| Vein-to-vein TAT | 3–6 weeks |
| Cold chain | Vapor-phase LN2 < −130C |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Legend Biotech detailing customer segments, channels, and value propositions across the 9 BMC blocks, reflecting its CAR‑T oncology platform, strategic partnerships, commercialization and R&D model, competitive advantages, risks and investor-ready insights for presentations and funding discussions.
Customizable Excel Spreadsheet
High-level view of Legend Biotech’s business model with editable cells, enabling rapid alignment of R&D, commercialization and partnership strategies while saving hours on formatting.
Activities
Cell therapy R&D
Design and optimization of CAR constructs and cell engineering methods drive Legend Biotech R&D, supporting ciltacabtagene autoleucel (Carvykti) commercialization after FDA approval in 2022. Rigorous preclinical efficacy and safety testing de-risks clinical entry and informs trial design. Platform innovations prioritize durability and safety while IP generation secures competitive positioning.
Clinical development
Execute multi-phase trials across hematologic and select solid tumors via the CARTITUDE program (CARTITUDE-1/2/3/4), leveraging cilta-cel data showing a 97.9% overall response rate in CARTITUDE-1 and FDA approval on February 28, 2022. Expand labels through line extensions and earlier-line studies to broaden indications. Orchestrate global sites, centralized monitoring, and strict data-integrity systems. Patient-centric designs (decentralized visits, home nursing) improve enrollment and outcomes.
GMP manufacturing
Scale GMP autologous processing with stringent QC/QA to support commercial supply of cilta-cel (Carvykti), which has a U.S. list price of about 465,000 per treated patient, driving the need to improve yields and reduce per-patient cost. Optimize cycle time and release testing to shorten vein-to-vein timelines while implementing digital batch records and analytics for real-time deviation control. Validate additional sites and contract partners to add redundancy and capacity for global rollout.
Regulatory and market access
Prepare regulatory submissions, respond to agency queries and meet post-approval commitments for cell therapy products (CARVYKTI received FDA approval in February 2022); build HTA value dossiers and economic models to support cost-effectiveness and budget impact; negotiate list prices, outcomes-based agreements and reimbursement pathways with payers; maintain global compliance and active pharmacovigilance for safety reporting.
- Regulatory filings: FDA approval Feb 2022
- HTA focus: value dossiers & economic models
- Commercial: pricing, outcomes-based contracts
- Compliance: global pharmacovigilance & post-market commitments
Commercialization and medical affairs
Commercialization and medical affairs educate HCPs and referral centers on patient selection and management, coordinate patient services and case management, generate real-world evidence to support uptake and reimbursement, and provide center training, logistics and quality programs; activity intensified following FDA approval in 2022 and global rollout with commercial partners through 2024.
- Educate HCPs/centers on referral and management
- Coordinate patient services & case management
- Generate & disseminate real-world evidence
- Support training, logistics & quality programs
Scale CAR-T autologous manufacturing, preserve CARTITUDE-1 safety/efficacy (ORR 97.9%)
Design and optimize CAR constructs and GMP autologous manufacturing to commercialize cilta-cel (FDA approved Feb 28, 2022), maintain safety/efficacy via preclinical and CARTITUDE trials (CARTITUDE-1 ORR 97.9%), and execute global regulatory, payer negotiations and post-market pharmacovigilance.
| Metric | Value |
|---|---|
| FDA approval | Feb 28, 2022 |
| CARTITUDE-1 ORR | 97.9% |
| US list price | ~465,000 per patient |
Delivered as Displayed
Business Model Canvas
The Business Model Canvas you’re previewing for Legend Biotech is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, fully formatted, and ready to edit. No surprises: what you see is what you’ll download and use.
Original: $10.00
-65%$10.00
$3.50Description
Biotech Business Model Canvas: Investor-ready roadmap for value creation and scalable growth
Unlock the full strategic blueprint behind Legend Biotech’s Business Model Canvas — a concise, actionable map of its value propositions, key partners, and revenue drivers. This professional, editable file is perfect for investors, strategists, and founders who need clear, company-specific insights. Purchase the full canvas to benchmark, plan, and scale with confidence.
Partnerships
Global pharma co-development
Strategic alliances with large pharma expand clinical, regulatory, and commercial reach, as Legend’s 2017 collaboration with Janssen (USD 350 million upfront, up to ~USD 2 billion in milestones) provided global regulatory and commercialization scale. Co-development accelerates trials and label expansions while sharing risk and costs. Joint commercialization strengthens market access and post-launch evidence, and structured governance ensures aligned portfolio prioritization.
Academic and clinical centers
Partnerships with leading cancer institutes enabled Legend Biotech’s clinical enrollment and translational research for cilta-cel, approved by the FDA in 2022, and continue to support ongoing registrational and post-marketing studies as of 2024. Access to KOLs refines protocols and endpoints, improving trial efficiency and regulatory dialogue. Real-world evidence generation strengthens payer health-economic cases, while shared biobanking accelerates biomarker discovery.
CDMOs and apheresis networks
CDMOs and apheresis networks extend Legend Biotech’s manufacturing footprint and patient reach, enabling production and collections across multiple geographies; as of 2024 Carvykti (cilta-cel) remains commercially distributed under this model. Standardized apheresis protocols improve starting material quality and reduce turnaround time for vein-to-vein workflows. Surge flexibility with contract partners mitigates demand spikes during launch or label expansions. Quality agreements enforce GMP and chain-of-identity controls across the supply chain.
Regulatory and HTA engagement
Early scientific advice aligns Legend Biotech development with regulatory expectations; CARVYKTI received FDA approval in February 2022, anchoring ongoing dialogue. HTA bodies define evidence requirements for reimbursement and real-world evidence; payer-led managed entry agreements can de-risk adoption. Continuous regulator and HTA engagement speeds submissions and post-approval variations.
- Regulatory: FDA approval Feb 2022
- HTA: informs evidence for reimbursement
- Managed entry: de-risks payer uptake
- Continuous dialogue: accelerates filings/variations
Technology and logistics providers
- Tracking: digital vein-to-vein platforms, 3–6 week TAT
- Cold chain: vapor-phase LN2 < −130C
- Analytics: real-time SPC, predictive maintenance
- Security: HIPAA and 21 CFR Part 11 compliance
USD 350M pharma deal and CDMO/cold-chain partners underpin commercial CAR-T scale (FDA Feb 2022)
Strategic pharma alliances (Janssen deal: USD 350M upfront, up to ~USD 2B), academic/clinical site networks, CDMO/apheresis partners, regulator/HTA engagement and digital cold-chain/analytics partners underpin commercial CARVYKTI scale (FDA approval Feb 2022) and ongoing 2024 registrational/post-marketing activity.
| Metric | Value (2024) |
|---|---|
| FDA approval | Feb 2022 |
| Janssen deal | USD 350M upfront; ~USD 2B milestones |
| Vein-to-vein TAT | 3–6 weeks |
| Cold chain | Vapor-phase LN2 < −130C |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Legend Biotech detailing customer segments, channels, and value propositions across the 9 BMC blocks, reflecting its CAR‑T oncology platform, strategic partnerships, commercialization and R&D model, competitive advantages, risks and investor-ready insights for presentations and funding discussions.
Customizable Excel Spreadsheet
High-level view of Legend Biotech’s business model with editable cells, enabling rapid alignment of R&D, commercialization and partnership strategies while saving hours on formatting.
Activities
Cell therapy R&D
Design and optimization of CAR constructs and cell engineering methods drive Legend Biotech R&D, supporting ciltacabtagene autoleucel (Carvykti) commercialization after FDA approval in 2022. Rigorous preclinical efficacy and safety testing de-risks clinical entry and informs trial design. Platform innovations prioritize durability and safety while IP generation secures competitive positioning.
Clinical development
Execute multi-phase trials across hematologic and select solid tumors via the CARTITUDE program (CARTITUDE-1/2/3/4), leveraging cilta-cel data showing a 97.9% overall response rate in CARTITUDE-1 and FDA approval on February 28, 2022. Expand labels through line extensions and earlier-line studies to broaden indications. Orchestrate global sites, centralized monitoring, and strict data-integrity systems. Patient-centric designs (decentralized visits, home nursing) improve enrollment and outcomes.
GMP manufacturing
Scale GMP autologous processing with stringent QC/QA to support commercial supply of cilta-cel (Carvykti), which has a U.S. list price of about 465,000 per treated patient, driving the need to improve yields and reduce per-patient cost. Optimize cycle time and release testing to shorten vein-to-vein timelines while implementing digital batch records and analytics for real-time deviation control. Validate additional sites and contract partners to add redundancy and capacity for global rollout.
Regulatory and market access
Prepare regulatory submissions, respond to agency queries and meet post-approval commitments for cell therapy products (CARVYKTI received FDA approval in February 2022); build HTA value dossiers and economic models to support cost-effectiveness and budget impact; negotiate list prices, outcomes-based agreements and reimbursement pathways with payers; maintain global compliance and active pharmacovigilance for safety reporting.
- Regulatory filings: FDA approval Feb 2022
- HTA focus: value dossiers & economic models
- Commercial: pricing, outcomes-based contracts
- Compliance: global pharmacovigilance & post-market commitments
Commercialization and medical affairs
Commercialization and medical affairs educate HCPs and referral centers on patient selection and management, coordinate patient services and case management, generate real-world evidence to support uptake and reimbursement, and provide center training, logistics and quality programs; activity intensified following FDA approval in 2022 and global rollout with commercial partners through 2024.
- Educate HCPs/centers on referral and management
- Coordinate patient services & case management
- Generate & disseminate real-world evidence
- Support training, logistics & quality programs
Scale CAR-T autologous manufacturing, preserve CARTITUDE-1 safety/efficacy (ORR 97.9%)
Design and optimize CAR constructs and GMP autologous manufacturing to commercialize cilta-cel (FDA approved Feb 28, 2022), maintain safety/efficacy via preclinical and CARTITUDE trials (CARTITUDE-1 ORR 97.9%), and execute global regulatory, payer negotiations and post-market pharmacovigilance.
| Metric | Value |
|---|---|
| FDA approval | Feb 28, 2022 |
| CARTITUDE-1 ORR | 97.9% |
| US list price | ~465,000 per patient |
Delivered as Displayed
Business Model Canvas
The Business Model Canvas you’re previewing for Legend Biotech is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact document—complete, fully formatted, and ready to edit. No surprises: what you see is what you’ll download and use.
